The FDA has put Cadence Pharma's application to market its pain and fever therapy on hold. The agency alerted Cadence that it couldn't approve the drug--to be marketed as Ofirmev--until manufacturing problems at a third-party facility were resolved. Cadence emphasized that the FDA did not ask for any new studies. Cadence release | Report